• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Extending adjuvant letrozole treatment may reduce breast cancer recurrence: The MA.17R trial

byMatthew Lin, MDandShaidah Deghan, MSc. MD
July 20, 2016
in Oncology, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Extended-use adjuvant letrozole therapy was associated with significant reduction in breast cancer-free survival but not overall survival, compared to placebo.

2. Extended-use adjuvant letrozole therapy was associated with significantly more bone toxicity side effects compared to placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Anti-estrogen therapies like tamoxifen, and aromatase inhibitors like letrozole have been used as adjuvant therapies to reduce recurrence of hormone receptor positive breast cancer. Typically, an aromatase inhibitor is used as either up-front monotherapy or used after a five-year course of tamoxifen therapy. In this double-blind, placebo controlled randomized trial, researchers evaluated the effects of extending adjuvant letrozole therapy by an additional five years to the standard of care in reducing breast cancer recurrence. Researchers found that extended use of letrozole for five years reduced the recurrence of breast cancer in women, independent of nodal status, previous adjuvant chemotherapy and duration of prior anti-estrogen or aromatase inhibitor therapy. However, no overall difference in overall survival was seen between participants treated with letrozole compared to placebo. Additionally, researchers noted significantly more bone toxic events in the letrozole group.

Click to read the study, published today in NEJM

Relevant Reading: A randomized trial of letrozole in postmenopausal women after five ears of tamoxifen therapy for early-stage breast cancer.

In-Depth [randomized controlled trial]: In this study, 1918 participants were randomized to receive either letrozole (n = 959) or placebo (n = 959). The primary study end-point was disease free survival from the time of randomization to the time of recurrence of either primary breast cancer or development of new primary breast cancer in the contralateral breast. Of the 165 participants that experienced disease recurrence, 40% were in the letrozole group and 60% were in the placebo group. In terms of death from disease recurrence, 31 and 34 deaths occurred in the letrozole and placebo groups, respectively. The 5-year disease free survival rate was 95% (95%CI 93-96) for the letrozole group and 91% (95%CI 89-93) for the placebo group, with a HR of 0.66 (95%CI 0.48-0.91; p = 0.01). However, the difference between the overall 5-year survival rate between the letrozole (93% rate; 95%CI 92-95) and control group (94% rate, 95%CI 92-95) was not significant (HR 0.97; p = 0.83).

RELATED REPORTS

Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

Letrozole and abemaciclib in estrogen receptor–positive recurrent endometrial cancer

The annual incidence rate of contralateral breast cancer in the letrozole group was 0.21% (95%CI 0.1-0.32) compared to the placebo rate of 0.49% (95%CI 0.32-0.67) with a hazard ratio of 0.42 (95%CI 0.22-0.81; p = 0.007). Bone related toxic effects occurred more frequently in the letrozole group. In the letrozole group, 10% of participants compared to 7% of placebo group participants had lumbar spine T-scores less than -2.5 at any time after baseline (p = 0.03). Additionally, new onset osteoporosis occurred in 109 (11%) of letrozole group participants compared to 54 (6%) of placebo group patients (p < 0.001). No significant differences between the groups were noted for overall SF-36 scores and corollary subscale scores (completed by 85% of participants). However, reduction in scores over time was greater in the letrozole group for the bodily-pain subscores. Only 5.4% and 3.7% of participants discontinued treatment in the letrozole and control groups, respectively.

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: breast cancer survivalletrozole
Previous Post

The SPRINT: Intensive vs. standard blood pressure control [Classics Series]

Next Post

Lower than expected seropositivity among vaccinated university students during N. meningitidis outbreak

RelatedReports

3D mammography (tomosynthesis) enhances accuracy of breast cancer screening
Chronic Disease

Less frequent mammography is non-inferior to annual screening for breast cancer survival in women after curative treatment

April 2, 2025
#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation
StudyGraphics

#VisualAbstract: Switch to fulvestrant and palbociclib may improve survival in patients with advanced breast cancer and ESR1 mutation

January 31, 2023
Recurrence of endometrial hyperplasia following medical therapy is common
Oncology

Letrozole and abemaciclib in estrogen receptor–positive recurrent endometrial cancer

December 28, 2022
#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
StudyGraphics

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

August 2, 2022
Next Post
Concomitant HPV vaccine administration equivalent to staggered schedule

Lower than expected seropositivity among vaccinated university students during N. meningitidis outbreak

Pediatric DKA associated with recent acute care visits

All glucose-lowering medications effective, but some offer lower hypoglycemia risks

Longer duration of elastic compression therapy may help prevent post-thrombotic syndrome

Longer duration of elastic compression therapy may help prevent post-thrombotic syndrome

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.